Meiji, Roche, Fedora Tie Up for Development, Commercialization of Beta-Lactamase Inhibitor

Meiji Seika Pharma, the Swiss-based drug giant Roche, and Canada’s Fedora Pharmaceuticals have entered into a license agreement to develop and commercialize the beta-lactamase inhibitor OP0595, Meiji Seika Pharma said on January 13. Under the terms of the deal, Roche...read more